Serratia marcescens and prodigiosin: a pigment with biotechnological potential
DOI:
https://doi.org/10.24197/wsc6ff44Keywords:
Serratia marcescens, prodigiosin, antitumor, inmunosuppressant, bactericidalAbstract
Serratia marcescens is a Gram-negative, facultative anaerobic bacillus belonging to the Enterobacteriaceae family. It is found in the environment and occasionally in the human gut microbiota. It is an opportunistic and nosocomial pathogen, primarily infecting immunocompromised patients. It is spread by contact and persists in moist environments and on biomedical materials (oxygenation devices, catheters, intravenous solutions, soaps, and sinks), causing infections such as ventilator-associated pneumonia, catheter-related bacteremia, catheter-related urinary tract infections, and surgical wound infections (1,2). However, only about 10% of clinical isolates of S. marcescens produce a pigment called prodigiosin, a red secondary metabolite whose presence is usually associated with less virulent strains of environmental origin (2). This pigment is being extensively studied for its potential use in various fields, especially in medicine and industry. Furthermore, it is harmless and safe for the environment (3).
Prodigiosin exhibits anticancer, immunosuppressive, bactericidal, and antifungal activities, and acts as a sunscreen enhancer. Its antitumor effect derives from its pro-apoptotic action, with cell cycle arrest, DNA damage, and alteration of intracellular pH—mechanisms that promote the elimination of cancerous cells. This activity has been documented in multiple cell lines (including lung, colon, breast, and liver cancers, as well as leukemia, among others), with minimal toxicity to non-tumor cells (4,5). In addition, prodigiosin acts as an immunomodulator by suppressing the activity of T lymphocytes and cytotoxic T lymphocytes, which supports its role as an immunosuppressant that could be used to prevent organ or tissue rejection after transplantation and for the management of autoimmune diseases. It also exhibits inhibitory activity against Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus avium; it crosses the bacterial membrane and alters essential enzymes of the cell cycle and metabolism, leading to the inhibition of bacterial growth. Furthermore, it shows toxicity against phytopathogenic fungi of agricultural importance. Finally, it increases the sun protection factor (SPF) of sunscreens marketed by the cosmetics industry, so it could be used as a functional ingredient in sunscreens, although studies in mammals are still needed to define its biosafety (4).
In conclusion, due to this broad functional spectrum, the main objective at present is to produce this bacterial pigment on a large scale for industrial use. However, studies are needed to make it feasible as a drug, as well as in vivo studies to define its safety and efficacy. It is also necessary to develop new genetic engineering strategies that allow for obtaining large quantities of prodigiosin at low cost and establishing it as an active biomolecule.
Downloads
References
1. González Romo F, Gómez-Luz Centelles ML, Merino Amador P, Pérez-Cecilia Carrera E, Rodríguez-Avial López-Doriga C. Enterobacterias: características generales. Enterobacterias oportunistas. En: Picazo de la Garza JJ, Prieto Prieto J, editores. Compendio de Microbiología. 2ª ed. Barcelona: GEA consultoría editorial SL; 2016. p. 127-130 Disponible en: https://tienda.elsevier.es/compendio-de-microbiologia-9788490229217.html
2. Mensa Pueyo J, Soriano Viladomiu A, López Suñé E, Poliakova Mazneva Y, Linares Mondejar P, Barberán López J. Tratamiento de las infecciones producidas por microorganismos específicos. En: Mensa J, Soriano A, editores. Guía de terapéutica antimicrobiana. 35ª ed. Barcelona: Editorial Antares; 2025. p. 569-570. Disponible en:
3. Siew-Wei S, Nathan S, Kiew-Lian W. Toxicity evaluation of prodigiosin from Serratia marcescens in a Caenorhabditis elegans model. AIP Conference Proceedings. 2016;1784(1): 020015. Disponible en: https://doi.org/10.1063/1.4966725
4. Andrade A, Alvarado-Martínez A, Tavares-Carreón F. Serratia marcescens y su prodigiosina, del milagro a la medicina e industria. Recursos Naturales y Sociedad. 2023;9(2):77-90. Disponible en: https://doi.org/10.18846/renaysoc.2023.09.09.02.0007
5. Ji S, Sun R, Xu K, Man Z, Ji J, Pu Y, Yin L, Zhang J, Pu Y. Prodigiosin induces apoptosis and inhibits autophagy via the extracellular signal-regulated kinase pathway in K562 cells. Toxicology in Vitro. 2019;60:107-115. Disponible en: https://doi.org/10.1016/j.tiv.2019.05.003.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Alfredo Sejas Claros, LAURA RITA IOTTI, MARTA DOMÍNGUEZ-GIL GONZÁLEZ

This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published at Clínica will have a Creative Commons Attribution 4.0 International License (CC BY 4.0).
The journal allows the authors to retain publishing rights. Authors may reprint their articles in other media without having to request authorization, provided they indicate that the article was originally published in Clínica.
